Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Dna X (SONM) Short-Term Debt repayments (2018 - 2019)

Dna X filings provide 2 years of Short-Term Debt repayments readings, the most recent being $3.2 million for Q3 2019.

On a quarterly basis, Short-Term Debt repayments fell 83.06% to $3.2 million in Q3 2019 year-over-year; TTM through Sep 2025 was $9.0 million, a N/A change, with the full-year FY2019 number at $5.6 million, down 92.52% from a year prior.
Short-Term Debt repayments hit $3.2 million in Q3 2019 for Dna X, down from $5.8 million in the prior quarter.
In the past five years, Short-Term Debt repayments ranged from a high of $29.0 million in Q2 2018 to a low of $123000.0 in Q1 2019.